Royal Philips has commenced patient enrolment for its Stellarex ILLUMENATE Below-the-Knee (BTK) Investigational Device Exemption (IDE) clinical trial in the US.

The global, prospective, randomised, multi-centre trial will compare the safety and effectiveness of the Philips’ Stellarex 0.014 drug-coated angioplasty balloon to percutaneous transluminal angioplasty (PTA) in critical limb ischemia (CLI) patients.

“The primary objective of the study is to demonstrate the benefits, safety and durability of the drug-coated balloon in BTK peripheral artery disease (PAD).”

Around 354 subjects are set to be enrolled into the trial at 45 sites across the US, Europe and Australia over the next 12-18 months.

The primary objective of the study is to demonstrate the benefits, safety and durability of the drug-coated balloon in BTK peripheral artery disease (PAD).

ILLUMENATE BTK study principal investigator Mahmood Razavi said: “Given the challenging chronic nature of BTK PAD, we are hoping to find that through sustained patency using Stellarex, we can improve healing, and reduce target lesion revascularisation and major amputation.”

The Stellarex drug-coated balloon has been developed to restore and maintain blood flow to arteries in patients suffering from PAD.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It leverages EnduraCoat technology that helps reduce drug loss during transit and facilitates efficient drug delivery to the treatment site. The device has already secured the European CE-Mark.

Royal Philips Image Guided Therapy Devices business leader Christopher Barys said: “Peripheral artery disease below the knee is challenging and Philips is committed to providing proven clinical solutions that positively impact patient outcomes.

“With Stellarex BTK, we have the potential to improve patient outcomes and decrease re-admission costs for those suffering from this complex disease state, while providing clinicians with the necessary tools to confirm the right therapies for their patients.”

Covidien, a Medtronic company, divested the Stellarex drug-coated balloon to Spectranetics in November 2014. Philips later acquired Spectranetics last year for €1.9bn.